For many active adults, the best path is not just medication
Nooms SmartDose protocol titrates slowly to minimize nausea, diarrhea, and fatigue
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial
Retatrutide could potentially tackle numerous obesity-related issues from cardiovascular to renal, positioning itself as a noteworthy contender in the upcoming metabolic disease arsenal
After 24 weeks of treatment, there were no observed changes in LV ejection fraction (LVEF), quality of life, or functional class
The pharmacological rationale traces back to over two decades of incretin research showing that GIP and GLP-1, although co-secreted from the gut after a meal, act through distinct -cell signalling pathways and are differentially affected in metabolic disease states